Asian Journal of Andrology

INVITED RESEARCH HIGHLIGHT
Year
: 2020  |  Volume : 22  |  Issue : 1  |  Page : 76--78

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer


Jeanny B Aragon-Ching 
 GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA

Correspondence Address:
Jeanny B Aragon-Ching
GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031
USA




How to cite this article:
Aragon-Ching JB. Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer.Asian J Androl 2020;22:76-78


How to cite this URL:
Aragon-Ching JB. Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer. Asian J Androl [serial online] 2020 [cited 2022 Nov 28 ];22:76-78
Available from: https://www.ajandrology.com/article.asp?issn=1008-682X;year=2020;volume=22;issue=1;spage=76;epage=78;aulast=Aragon-Ching;type=0